Oncology Business Management

In another discovery that may help tailor the treatment of women with breast cancer, researchers from the Dana-Farber Women's Cancers Program determined that overexpression of the LAPTM4B and YWHAZ genes on chromosome 8q22, combined with amplification of other genes, conveys resistance to anthracyclines and increases the likelihood of metastatic recurrence.

Chemotherapy recipients have long complained of decreased mental function during and after treatment, yet the medical community has only recently acknowledged the reality of chemo brain, the term for chemotherapy's degenerative effect on normal cognitive function.

The Ancient Indians were the fi rst to use pens around 5000 BCE. While these writing implements were primitive, typically consisting of hollowed out reeds that could hold a small amount of ink, which was generally soot in water with a plant gum binder, they were used for thousands of years and are still used today in certain parts of Pakistan.

Once a human malignancy metastasizes, currently available cytotoxic chemotherapy is usually palliative. While conventional chemotherapy regimens are associated with objective tumor regression, this only occurs in a minority of patients.

The Third Annual IPCC: "Translating Advances into Clinical Practice," is to be held in New York City on Saturday, March 27, 2010. Recent developments in the prevention, diagnosis, and treatment of prostate cancer most relevant to community-based physicians will form the core areas of discussion.

Oncology & Biotech News (OBTN) starts its fourth year of publication with a new look and an even stronger focus on bringing you the latest developments in clinical trial research, practice guidelines, and regulatory information.

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is one of only 40 cancer centers in the country designated by the National Cancer Institute as a Comprehensive Center. The physician researchers at the institution have been characterizing the acquired genome defects in cancers for the better part of the past few decades.

Executives at Radient Pharmaceuticals Corporation may one day look back on 2009 as the year when the coming-out party for the two-decades-old firm located in Tustin, California, began.

If there is such a thing as a business trifecta, Seattle Genetics is nearly there. The Washington state biotechnology company is focused on the development and commercialization of monoclonal antibody–based therapies for the treatment of cancer and autoimmune disease. And with a potent pipeline of potential products and numerous technology and marketing collaborations in place, the opportunities for growth are in the air.

When companies talk about "narrowing the gap," they typically mean closing the distance that separates them from their leading competitor. At Ariad Pharmaceuticals, however, that expression has taken on a new meaning: narrowing the distance from development to market for its two most promising compounds.

At the 2010 Gastrointestinal Cancers Symposium, researchers from two studies reported that the Oncotype DX colon cancer test, combined with extended lymph node assessment,helped identify patients at high risk of recurrence for stage II colorectal cancer after surgery.

A study presented at the 51st American Society of Hematology Meeting and Expedition reported that 5 days of palonosetron (Aloxi) was significantly more effective than ondansetron at preventing delayed chemotherapy-induced nausea and vomiting (CINV) in patients with acute myelogenous leukemia (AML).

Sunitinib malate (Sutent)doubled progression-free survival (PFS) in a phase III trial involving patients with pancreatic neuroendocrine tumors (NETs). Data were presented at the 2010 Gastrointestinal Cancers Symposium in January.

At the 2010 Gastrointestinal Cancers Symposium, new data from the CRYSTAL trial identified BRAF gene mutations as a poor prognostic indicator in metastatic colorectal cancer (mCRC) but not predictive of response to therapy.

August has traditionally been a sleepy month for government regulatory agencies, but this year, Washington's usual summer torpor was interrupted by a rush of new initiatives, as more than three-quarters of a trillion dollars from the American Recovery and Reinvestment Act surged into a mind- boggling range of projects.

The American Recovery and Reinvestment Act (ARRA) of 2009 designated $87 billion for state Medicaid programs, enacting major increases in federal matching rates. Despite the boost from ARRA, state budgets have been groaning under the weight of the economic downturn, with 29 of them planning to make Medicaid cuts in 2010.

Advances in diagnostic imaging have led to general improvement in treating patients for various maladies. Recently, advances in breast diagnostic imaging with magnetic resonance imaging (MRI) in unselected patient populations have exposed a number of pitfalls that threaten well-established, data-proven medical practice.

The use of oral oncolytics is increasing, with 14 approved already and nearly one-quarter of the oncology pipeline consisting of oral therapies. Despite this, the Community Oncology Alliance (COA), a nonprofit organization that advocates for patients and providers in the community oncology setting, said many patients still have difficulty getting access`to targeted oral oncolytics.

The potential federal healthcare overhaul engendered a bitter debate over rumored "death panels" making end-of-life decisions for patients. Although the claims were never substantiated, the furor directed the nation's attention to the important issue of end-of-life care.

The December issue of Oncology & Biotech News featured highlights from the 51st American Society of Hematology (ASH) Annual Meeting and Exposition. We wrap up our ASH coverage this month with interviews on multiple myeloma with Brian G.M. Durie, MD, medical director and co-founder of the International Myeloma Foundation; chronic lymphocytic leukemia (CLL) with Robert J. Kreitman, MD, from the National Cancer Institute; and chronic myeloid leukemia (CML) with Francis J. Giles, MD, Cancer Therapy and Research Center at The University of Texas Health Science Center in San Antonio.

Participation in clinical trial research is essential to continued improvement in cancer care. Yet, fewer than 10% of U.S. adults enroll in trials. A recent US Oncology�sponsored survey found that most oncologists remain optimistic about the future of clinical trial research. We discuss obstacles to clinical trial enrollment with Nicholas Vogelzang, MD, and Matthew Galsky, MD, of the Comprehensive CancerCenters of Nevada.

The Third Annual Interdisciplinary Prostate Cancer Congress (IPCC) will take place on Saturday March 27, 2010, in New York City.

A persistent concern about using marijuana for medical purposes has been the lack of clinical trials demonstrating marijuana's effectiveness in any of the conditions for which it is legally prescribed in many states. Now, a team of researchers from the University of California San Diego School of Medicine's Center for Medicinal Cannabis Research (CMCR) has presented a summary of studies to the California legislature that claims smoking marijuana relieves pain in several chronic illnesses.

On January 29, the FDA expanded indications for lapatinib (Tykerb) to include its use in combination with the aromatase inhibitor letrozole (Femara) to treat hormone-positive and HER2-positive advanced breast cancer in postmenopausal women.